

Koji Sasaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5759175/publications.pdf>

Version: 2024-02-01

320
papers

6,872
citations

70961

41
h-index

85405

71
g-index

326
all docs

326
docs citations

326
times ranked

5313
citing authors

#	ARTICLE	IF	CITATIONS
1	Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2023, 98, .	2.0	11
2	Prediction of early (4â€week) mortality in acute myeloid leukemia with intensive chemotherapy. <i>American Journal of Hematology</i> , 2022, 97, 68-78.	2.0	25
3	Improved survival of patients with myelofibrosis in the last decade: Singleâ€center experience. <i>Cancer</i> , 2022, , .	2.0	16
4	Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. <i>Blood Advances</i> , 2022, 6, 3027-3035.	2.5	17
5	Improved outcomes among newly diagnosed patients with <scp>FMSâ€like tyrosine kinase 3 internal tandem duplication</scp> mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. <i>American Journal of Hematology</i> , 2022, 97, 329-337.	2.0	15
6	Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). <i>Blood Cancer Journal</i> , 2022, 12, 5.	2.8	49
7	Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. <i>Leukemia</i> , 2022, 36, 1253-1260.	3.3	9
8	Dismal outcomes of patients with relapsed/refractory Philadelphia chromosomeâ€negative Bâ€cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	7
9	Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 1714-1717.	0.6	3
10	<scp>Treatmentâ€free</scp> remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 856-864.	2.0	33
11	Prediction of survival with intensive chemotherapy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 865-876.	2.0	12
12	Prediction for sustained deep molecular response for treatment-free remission. <i>Leukemia and Lymphoma</i> , 2022, 63, 5-6.	0.6	0
13	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. <i>American Journal of Hematology</i> , 2022, 97, 885-894.	2.0	4
14	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2161-2170.	0.6	12
15	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. <i>Lancet Haematology</i> , the, 2022, 9, e350-e360.	2.2	26
16	Hypomethylating agent and venetoclax with FLT3 inhibitor â€œtripletâ€ therapy in older/unfit patients with FLT3 mutated AML. <i>Blood Cancer Journal</i> , 2022, 12, 77.	2.8	33
17	Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. <i>Modern Pathology</i> , 2022, 35, 1212-1219.	2.9	10
18	<i>TP53</i>â€altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitorâ€based therapy: A retrospective analysis. <i>American Journal of Hematology</i> , 2022, 97, 1005-1012.	2.0	6

#	ARTICLE	IF	CITATIONS
19	Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1035-1043.	2.0	31
20	Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects. <i>Cancers</i> , 2022, 14, 2533.	1.7	6
21	Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10^{-4} and higher. <i>American Journal of Hematology</i> , 2022, 97, 1135-1141.	2.0	6
22	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3848-3857.	0.8	41
23	Real-life incidence of thrombotic events in leukemia patients treated with ponatinib. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	4
24	Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. <i>Haematologica</i> , 2021, 106, 894-898.	1.7	80
25	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E50-E53.	2.0	8
26	Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia – a distinct subtype with favorable prognosis. <i>Leukemia and Lymphoma</i> , 2021, 62, 224-228.	0.6	6
27	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. <i>American Journal of Hematology</i> , 2021, 96, 282-291.	2.0	59
28	The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. <i>American Journal of Hematology</i> , 2021, 96, 241-250.	2.0	19
29	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. <i>Cancer</i> , 2021, 127, 381-390.	2.0	10
30	Examination of the best head tilt angle to reduce the parotid gland dose maintaining a safe level of lens dose in whole-brain radiotherapy using the four-field box technique. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 49-57.	0.8	2
31	Two Cases of Possible Familial Chronic Myeloid Leukemia in a Family with Extensive History of Cancer. <i>Acta Haematologica</i> , 2021, 144, 585-590.	0.7	3
32	Decitabine and venetoclax for IDH1/2 mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E154-E157.	2.0	19
33	Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. <i>Leukemia Research</i> , 2021, 101, 106511.	0.4	4
34	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. <i>Blood Cancer Journal</i> , 2021, 11, 52.	2.8	5
35	Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. <i>American Journal of Hematology</i> , 2021, 96, 589-598.	2.0	42
36	Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 2025-2038.	2.0	24

#	ARTICLE	IF	CITATIONS
37	Current status and novel strategy of CML. <i>International Journal of Hematology</i> , 2021, 113, 624-631.	0.7	11
38	Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (<sc>MDS/MPN</sc>) and myelodysplastic syndrome with ring sideroblasts (<sc>MDS</sc>). <i>American Journal of Hematology</i> , 2021, 96, E246-E249.	2.0	9
39	Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. <i>Blood Advances</i> , 2021, 5, 2173-2183.	2.5	35
40	Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2489-2499.	2.0	34
41	Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. <i>Cancer</i> , 2021, 127, 3113-3124.	2.0	5
42	Acute lymphoblastic leukemia: A population-based study of outcome in the <sc>United States</sc> based on the surveillance, epidemiology, and end results (<sc>SEER</sc>) database, <sc>1980</sc>â€<sc>2017</sc>. <i>American Journal of Hematology</i> , 2021, 96, 650-658.	2.0	52
43	Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. <i>Cancer</i> , 2021, 127, 2648-2656.	2.0	33
44	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. <i>Cancer</i> , 2021, 127, 2641-2647.	2.0	15
45	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883.	2.5	56
46	Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 1494-1499.	3.3	16
47	De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. <i>Cancer</i> , 2021, 127, 2049-2061.	2.0	79
48	Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 338-344.	0.2	7
49	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (IFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. <i>Leukemia</i> , 2021, 35, 3421-3429.	3.3	22
50	Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2021, 194, 61-68.	1.2	2
51	Lung dose reduction in patients with stage III non-small-cell lung cancer using software that estimates patient-specific dose reduction feasibility. <i>Physica Medica</i> , 2021, 85, 57-62.	0.4	3
52	Impact of frontline treatment approach on outcomes of myeloid blast phase CML. <i>Journal of Hematology and Oncology</i> , 2021, 14, 94.	6.9	19
53	Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1733-1739.	0.6	19
54	Outcomes in patients with newly diagnosed <i>TP53</i>-mutated acute myeloid leukemia with or without venetoclax-based therapy. <i>Cancer</i> , 2021, 127, 3541-3551.	2.0	40

#	ARTICLE	IF	CITATIONS
55	Hyper-CD20 plus ofatumumab versus hyper-CD20 plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2021, 127, 3381-3389.	2.0	10
56	Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. <i>Cancer</i> , 2021, 127, 3552-3565.	2.0	19
57	Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. <i>Cancer</i> , 2021, 127, 3772-3781.	2.0	80
58	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2021, 7, 1213.	3.4	53
59	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. <i>Blood</i> , 2021, 138, 2031-2041.	0.6	147
60	Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 3402-3410.	0.6	12
61	Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. <i>Blood Cancer Journal</i> , 2021, 11, 162.	2.8	32
62	Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. <i>Leukemia and Lymphoma</i> , 2021, , 1-5.	0.6	2
63	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 2768-2778.	0.8	173
64	The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. <i>Haematologica</i> , 2021, 106, 2853-2858.	1.7	15
65	Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. <i>Haematologica</i> , 2021, 106, 0-0.	1.7	6
66	Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant. <i>Acta Haematologica</i> , 2021, 144, 285-292.	0.7	10
67	Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors. <i>Blood</i> , 2021, 138, 1480-1480.	0.6	2
68	Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. <i>Leukemia</i> , 2020, 34, 872-881.	3.3	22
69	The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. <i>American Journal of Hematology</i> , 2020, 95, 144-150.	2.0	25
70	Questionnaire survey on treatment planning techniques for lung stereotactic body radiotherapy in Japan. <i>Journal of Radiation Research</i> , 2020, 61, 104-116.	0.8	9
71	Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 765-774.	2.0	69
72	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e724-e736.	2.2	201

#	ARTICLE	IF	CITATIONS
73	Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. <i>Cancer</i> , 2020, 126, 4322-4331.	2.0	19
74	Dosimetric effects of dose calculation grid size on the epidural space dose. <i>Medical Dosimetry</i> , 2020, 45, 327-333.	0.4	1
75	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e523-e533.	2.2	43
76	Survivorship in AML – a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. <i>Leukemia and Lymphoma</i> , 2020, 61, 3120-3127.	0.6	12
77	A Relationship Between Cervical Vertebrae Twisting and Cranial Angle in Head and Neck Radiotherapy. <i>In Vivo</i> , 2020, 34, 2401-2406.	0.6	2
78	Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). <i>American Journal of Hematology</i> , 2020, 95, E326-E329.	2.0	2
79	Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 48.	2.8	22
80	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. <i>Blood Cancer Journal</i> , 2020, 10, 61.	2.8	20
81	Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. <i>Modern Pathology</i> , 2020, 33, 1678-1689.	2.9	16
82	Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020, 95, 734-739.	2.0	10
83	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. <i>American Journal of Hematology</i> , 2020, 95, 612-622.	2.0	51
84	LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. <i>Leukemia and Lymphoma</i> , 2020, 61, 1493-1499.	0.6	14
85	Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. <i>Acta Haematologica</i> , 2020, 143, 567-573.	0.7	53
86	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 482-495.	2.5	86
87	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. <i>Blood Advances</i> , 2020, 4, 1311-1320.	2.5	106
88	Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. <i>Frontiers in Oncology</i> , 2020, 10, 582213.	1.3	33
89	Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. <i>Blood</i> , 2020, 136, 18-20.	0.6	17
90	Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation. <i>Blood</i> , 2020, 136, 36-37.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 22-25.	0.6	2
92	Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure. <i>Blood</i> , 2020, 136, 22-23.	0.6	2
93	Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents. <i>Blood</i> , 2020, 136, 1-3.	0.6	2
94	Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression. <i>Blood</i> , 2020, 136, 38-40.	0.6	1
95	Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2020, 136, 21-22.	0.6	1
96	A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2020, 136, 7-9.	0.6	17
97	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. <i>Blood</i> , 2020, 136, 42-43.	0.6	11
98	Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacitidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 17-19.	0.6	10
99	Response and Survival Outcomes with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia Based on Disease Phenotype and Risk Categories. <i>Blood</i> , 2020, 136, 8-9.	0.6	1
100	Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). <i>Blood</i> , 2020, 136, 32-34.	0.6	2
101	Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in		

#	ARTICLE	IF	CITATIONS
109	Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib. <i>Blood</i> , 2020, 136, 40-41.	0.6	2
110	Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and Dasatinib. <i>Blood</i> , 2020, 136, 46-48.	0.6	0
111	Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort. <i>Blood</i> , 2020, 136, 44-45.	0.6	1
112	Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis. <i>Blood</i> , 2020, 136, 4-5.	0.6	0
113	A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab. <i>Blood</i> , 2020, 136, 2-4.	0.6	0
114	Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis. <i>Blood</i> , 2020, 136, 42-43.	0.6	0
115	Role of Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 39-41.	0.6	0
116	Clinical Course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma. <i>Blood</i> , 2020, 136, 25-26.	0.6	0
117	Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors. <i>Blood</i> , 2020, 136, 25-26.	0.6	6
118	Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series. <i>Blood</i> , 2020, 136, 18-19.	0.6	2
119	Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study. <i>Blood</i> , 2020, 136, 46-47.	0.6	0
120	The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis. <i>Blood</i> , 2020, 136, 3-5.	0.6	0
121	Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 45-47.	0.6	0
122	Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse. <i>Blood</i> , 2020, 136, 36-38.	0.6	0
123	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. <i>Blood</i> , 2020, 136, 43-45.	0.6	10
124	Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2020, 136, 3-4.	0.6	0
125	Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
126	Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors. <i>Blood</i> , 2020, 136, 42-44.	0.6	3

#	ARTICLE	IF	CITATIONS
127	Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS). <i>Blood</i> , 2020, 136, 18-19.	0.6	1
128	CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 23-25.	0.6	1
129	High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. <i>Leukemia and Lymphoma</i> , 2019, 60, 442-452.	0.6	15
130	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3 internal tandem duplication mutation positive acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3755-3766.	2.0	38
131	Development of twist correction system for radiotherapy of head and neck cancer patients. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 128-134.	0.8	6
132	Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?. <i>Cancer</i> , 2019, 125, 3891-3892.	2.0	0
133	Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 187, 543-545.	1.2	24
134	Inotuzumab Ozogamicin Combined with Low-Intensity, with or without Blinatumomab vs. Intensive Therapy for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S181.	0.2	0
135	Reduced-Intensity Chemotherapy Plus Inotuzumab Ozogamicin, With or Without Sequential Blinatumomab, is Highly Effective as First Salvage Treatment in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S186-S187.	0.2	0
136	The Impact of Smoking on Relapse and Survival in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S180.	0.2	0
137	Dynamic Prediction of Outcome with Longitudinal BCR-ABL1 Levels in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S180-S181.	0.2	0
138	Hyper-CVAD Plus Ofatumumab as Frontline Therapy for Adults with CD20 Positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S185.	0.2	0
139	Duplex Sequencing Identifies Low Level ABL1 Kinase Domain Mutations in Untreated Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S186.	0.2	0
140	The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia is a Strong Predictor for Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S193-S194.	0.2	1
141	LILRB4 Expression in CMML and MDS Based on Response to Hypomethylating Agents. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S341.	0.2	0
142	Ibrutinib and Venetoclax for First-Line Treatment of CLL. <i>New England Journal of Medicine</i> , 2019, 380, 2095-2103.	13.9	388
143	Prognostic significance of baseline FLT3 mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. <i>American Journal of Hematology</i> , 2019, 94, 984-991.	2.0	32
144	Impact of treatment planning using a structure block function on the target and organ doses related to patient movement in cervical esophageal cancer: A phantom study. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 75-83.	0.8	1

#	ARTICLE	IF	CITATIONS
145	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2019, 125, 2579-2586.	2.0	63
146	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2019, 109, 545-552.	0.7	25
147	Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. <i>Cancer</i> , 2019, 125, 2233-2241.	2.0	19
148	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. <i>Blood Advances</i> , 2019, 3, 851-861.	2.5	88
149	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. <i>Blood Advances</i> , 2019, 3, 922-933.	2.5	84
150	A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. <i>American Journal of Hematology</i> , 2019, 94, 74-79.	2.0	10
151	Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 2647-2647.	0.6	11
152	Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 823-823.	0.6	12
153	Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 283-283.	0.6	34
154	Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2019, 134, 1641-1641.	0.6	11
155	Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2019, 134, 3819-3819.	0.6	5
156	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. <i>Blood</i> , 2019, 134, 2637-2637.	0.6	15
157	Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 645-645.	0.6	9
158	Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs). <i>Blood</i> , 2019, 134, 1296-1296.	0.6	4
159	Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse. <i>Blood</i> , 2019, 134, 3806-3806.	0.6	11
160	Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). <i>Blood</i> , 2019, 134, 2642-2642.	0.6	2
161	Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 1715-1715.	0.6	2
162	Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). <i>Blood</i> , 2019, 134, 3807-3807.	0.6	21

#	ARTICLE	IF	CITATIONS
163	The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood, 2019, 134, 1642-1642.	0.6	4
164	Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL). Blood, 2019, 134, 3810-3810.	0.6	9
165	Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS). Blood, 2019, 134, 678-678.	0.6	26
166	Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis. Blood, 2019, 134, 1656-1656.	0.6	5
167	The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. Blood, 2019, 134, 1436-1436.	0.6	4
168	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. Blood, 2019, 134, 830-830.	0.6	38
169	Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 2019, 134, 359-359.	0.6	11
170	Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome. Blood, 2019, 134, 3016-3016.	0.6	5
171	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2019, 134, 34-34.	0.6	3
172	Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia. Blood, 2019, 134, 2640-2640.	0.6	12
173	Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy. Blood, 2019, 134, 1312-1312.	0.6	6
174	Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR). Blood, 2019, 134, 287-287.	0.6	0
175	The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong Predictor for Survival. Blood, 2019, 134, 1297-1297.	0.6	0
176	Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs). Blood, 2019, 134, 2941-2941.	0.6	1
177	Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood, 2019, 134, 2577-2577.	0.6	3
178	Transcriptomic Analysis Implicates Necroptosis in Disease Progression and Prognosis in Myelodysplastic Syndromes. Blood, 2019, 134, 3006-3006.	0.6	0
179	The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). Blood, 2019, 134, 3815-3815.	0.6	0
180	Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome. Blood, 2019, 134, 1720-1720.	0.6	0

#	ARTICLE	IF	CITATIONS
181	High-Resolution Next-Generation Whole Genome Optical Mapping As a Novel Molecular Diagnostic Tool for Comprehensive Assessment of Structural Chromosomal Variations in Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 5438-5438.	0.6	0
182	Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1719-1719.	0.6	0
183	Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 1711-1711.	0.6	0
184	Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy. <i>Blood</i> , 2019, 134, 647-647.	0.6	0
185	Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet. <i>Blood</i> , 2019, 134, 2930-2930.	0.6	0
186	Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS). <i>Blood</i> , 2019, 134, 2578-2578.	0.6	1
187	A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs). <i>Blood</i> , 2019, 134, 4237-4237.	0.6	0
188	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 240-248.	5.1	192
189	Prediction for sustained deep molecular response of $BCR\text{-}ABL1$ levels in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2018, 124, 1160-1168.	2.0	23
190	A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 813-820.	0.6	16
191	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Miniâ€“Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosomeâ€“Negative Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 230.	3.4	124
192	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1788-1797.	0.8	156
193	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. <i>Lancet Haematology,the</i> , 2018, 5, e618-e627.	2.2	190
194	Chemoimmunotherapy with inotuzumab ozogamicin combined with miniâ€“hyperâ€“CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia in first salvage. <i>Cancer</i> , 2018, 124, 4044-4055.	2.0	88
195	Interfacility variation in treatment planning parameters in tomotherapy: field width, pitch, and modulation factor. <i>Journal of Radiation Research</i> , 2018, 59, 664-668.	0.8	7
196	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. <i>Lancet Haematology,the</i> , 2018, 5, e411-e421.	2.2	66
197	Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 696-696.	0.6	17
198	Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. <i>Blood</i> , 2018, 132, 2674-2674.	0.6	1

#	ARTICLE	IF	CITATIONS
199	Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 286-286.	0.6	19
200	Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2018, 132, 36-36.	0.6	12
201	Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial. <i>Blood</i> , 2018, 132, 553-553.	0.6	17
202	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. <i>Blood</i> , 2018, 132, 34-34.	0.6	4
203	Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 1548-1548.	0.6	2
204	Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 232-232.	0.6	11
205	Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis. <i>Blood</i> , 2018, 132, 5513-5513.	0.6	5
206	A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). <i>Blood</i> , 2018, 132, 32-32.	0.6	14
207	Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 4017-4017.	0.6	5
208	Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. <i>Blood</i> , 2018, 132, 3983-3983.	0.6	2
209	A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 465-465.	0.6	48
210	A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7041-7041.	0.8	12
211	Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 1814-1814.	0.6	0
212	Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes. <i>Blood</i> , 2018, 132, 1514-1514.	0.6	0
213	The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 4359-4359.	0.6	0
214	Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). <i>Blood</i> , 2018, 132, 2664-2664.	0.6	0
215	Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen. <i>Blood</i> , 2018, 132, 1417-1417.	0.6	0
216	Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia. <i>Blood</i> , 2018, 132, 3013-3013.	0.6	2

#	ARTICLE	IF	CITATIONS
217	Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2791-2791.	0.6	0
218	Dynamic Personalized Assessment of Outcome in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 2695-2695.	0.6	0
219	Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1820-1820.	0.6	0
220	Analysis of modulation factor to shorten the delivery time in helical tomotherapy. <i>Journal of Applied Clinical Medical Physics</i> , 2017, 18, 83-87.	0.8	8
221	<i>t(9;22)</i> mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. <i>Cancer</i> , 2017, 123, 3717-3724.	2.0	18
222	Poor outcomes associated with +der(22)t(9;22) and <i>t(9;22)</i> in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. <i>American Journal of Hematology</i> , 2017, 92, 238-243.	2.0	41
223	Modified <i>CVAD</i> and modified <i>CBAD</i> compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 388-392.	1.1	12
224	Frontline Ofatumumab with Hyper-CVAD in CD20+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S256-S257.	0.2	2
225	A Phase II Trial of Inotuzumab Ozogamicin Combined with Mini-HyperCVD as Salvage Therapy for Relapsed/Refractory ALL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S264-S265.	0.2	0
226	Phase II study of hyper-CMAD with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S266.	0.2	0
227	Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S255-S256.	0.2	0
228	Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. <i>Blood</i> , 2017, 130, 2084-2091.	0.6	65
229	Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S257-S258.	0.2	1
230	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 4430-4439.	2.0	37
231	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. <i>Cancer</i> , 2017, 123, 4391-4402.	2.0	114
232	Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. <i>Blood</i> , 2017, 130, 1514-1522.	0.6	151
233	Clinical characteristics and outcomes of previously untreated patients with adult onset acute lymphoblastic leukemia and acute lymphoblastic lymphoma with hyper-CVAD based regimens. <i>American Journal of Hematology</i> , 2017, 92, E595-E597.	2.0	8
234	Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory <i>Bcr/abl</i> acute lymphoblastic leukemia. <i>Cancer</i> , 2017, 123, 294-302.	2.0	70

#	ARTICLE	IF	CITATIONS
235	Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. <i>Cancer</i> , 2017, 123, 629-637.	2.0	31
236	Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. <i>Cancer</i> , 2017, 123, 459-467.	2.0	49
237	Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7013-7013.	0.8	18
238	Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7014-7014.	0.8	2
239	Updated results of frontline ofatumumab-hyper-CVAD in adults with CD20+ acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7033-7033.	0.8	3
240	Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. <i>Cancer</i> , 2016, 122, 2857-2866.	2.0	88
241	Myeloablative Timed Sequential Busulfan Is Safe in Patients with Relapsed or High-Risk Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S228-S229.	2.0	0
242	Viral Reactivation in Haploidentical Transplants Using Post-Transplantation Cyclophosphamide â€” a Single Institution Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S375-S376.	2.0	7
243	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. <i>Blood</i> , 2016, 127, 1269-1275.	0.6	119
244	Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Cancer</i> , 2016, 122, 3812-3820.	2.0	17
245	Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2016, 122, 3650-3656.	2.0	156
246	Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 616-624.	0.2	11
247	A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2016, 122, 3336-3343.	2.0	14
248	Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. <i>Haematologica</i> , 2016, 101, e324-e327.	1.7	5
249	Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood</i> , 2016, 128, 504-507.	0.6	194
250	Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. <i>Cancer</i> , 2016, 122, 238-248.	2.0	30
251	Analysis of 2013 European LeukaemiaNet (<scp>ELN</scp>) responses in chronic phase <scp>CML</scp> across four frontline <scp>TKI</scp> modalities and impact on clinical outcomes. <i>British Journal of Haematology</i> , 2016, 173, 114-126.	1.2	19
252	Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 36-42.	0.2	5

#	ARTICLE	IF	CITATIONS
253	Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 152-162.	0.2	25
254	Rotational output and beam quality evaluations for helical tomotherapy with use of a third-party quality assurance tool. <i>Radiological Physics and Technology</i> , 2016, 9, 53-59.	1.0	1
255	A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. <i>Blood</i> , 2016, 128, 226-226.	0.6	3
256	Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. <i>Blood</i> , 2016, 128, 2783-2783.	0.6	6
257	Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy. <i>Blood</i> , 2016, 128, 3166-3166.	0.6	1
258	Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. <i>Blood</i> , 2016, 128, 3975-3975.	0.6	2
259	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. <i>Blood</i> , 2016, 128, 588-588.	0.6	11
260	Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 757-757.	0.6	2
261	Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase. <i>Blood</i> , 2016, 128, 940-940.	0.6	4
262	Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) + ponatinib vs. HCVAD + dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7025-7025.	0.8	1
263	Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7036-7036.	0.8	3
264	Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7042-7042.	0.8	1
265	Prognostic impact of pre-treatment cytogenetics in adult acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7038-7038.	0.8	0
266	Impact of complete molecular response (CMR) on survival in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7034-7034.	0.8	0
267	Prognostic significance of day 14 (D14) bone marrow (BM) assessment in adult patients receiving induction for Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7035-7035.	0.8	0
268	Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality. <i>Blood</i> , 2016, 128, 1737-1737.	0.6	0
269	Methotrexate Clearance in Adult Patients with B-Precursor Acute Lymphoblastic Leukemia Treated with the Mini-Hyper-CVD Regimen. <i>Blood</i> , 2016, 128, 5194-5194.	0.6	0
270	Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). <i>Blood</i> , 2016, 128, 1224-1224.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients. <i>Blood</i> , 2016, 128, 1220-1220.	0.6	0
272	Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S202-S203.	2.0	0
273	Prognostic Factors in Patients with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S172-S173.	0.2	0
274	Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a <sc>CD</sc>22 monoclonal antibody. <i>American Journal of Hematology</i> , 2015, 90, 193-196.	2.0	35
275	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. <i>Lancet Haematology</i> , the, 2015, 2, e186-e193.	2.2	227
276	Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2015, 56, 2092-2097.	0.6	51
277	Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2015, 5, 29.	1.3	3
278	Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. <i>Lancet Haematology</i> , the, 2015, 2, e118-e128.	2.2	65
279	High-grade neuroendocrine carcinoma of the bladder (large cell and small cell mixed): a literature review and case report of a rare bladder tumor. <i>International Cancer Conference Journal</i> , 2015, 4, 249-253.	0.2	2
280	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 1547-1555.	5.1	245
281	Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. <i>Haematologica</i> , 2015, 100, 1058-63.	1.7	46
282	Inotuzumab Ozogamicin (IO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) as Frontline Therapy for Older Patients (pts) and as Salvage Therapy for Adult with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S171.	0.2	5
283	Impact of Therapy-Related De Novo Acute Myeloid Leukemia on Response and Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S181-S182.	0.2	0
284	Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 1295-1295.	0.6	8
285	Outcome of Patients with Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) after Failure of Inotuzumab Ozogamicin. <i>Blood</i> , 2015, 126, 1298-1298.	0.6	2
286	Outcomes of Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphocytic Leukemia (ALL) Post Blinatumomab Failure. <i>Blood</i> , 2015, 126, 1335-1335.	0.6	1
287	Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015, 126, 2877-2877.	0.6	1
288	Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 3721-3721.	0.6	13

#	ARTICLE	IF	CITATIONS
289	Qualitative and Quantitative Correlation of PML-Rara Fusion Transcript from Peripheral Blood and Bone Marrow Samples By Quantitative Real-Time PCR in Patients with Acute Promyelocytic Leukemia. Blood, 2015, 126, 3756-3756.	0.6	1
290	Impact of the Type of BCR-ABL Fusion Transcripts on Response and Survival in Patients with Chronic Phase CML Treated with Four Frontline TKI Modalities. Blood, 2015, 126, 598-598.	0.6	1
291	Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 83-83.	0.6	19
292	Frontline Hyper-CVAD with Ponatinib for Patients (pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study. Blood, 2015, 126, 2496-2496.	0.6	0
293	Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial. Blood, 2015, 126, 2508-2508.	0.6	0
294	Prognostic Implications of Pre-Treatment Hypodiploidy and Complex Cytogenetics in Adult Patients with Acute Lymphocytic Leukemia (ALL) Treated with Hyper-CVAD. Blood, 2015, 126, 4874-4874.	0.6	0
295	Outcome of Patients with T-Cell ALL Post Frontline Therapy Failure. Blood, 2015, 126, 4873-4873.	0.6	0
296	The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 3771-3771.	0.6	0
297	Results of Intensive Chemotherapy in 434 Adult Patients (pts) with Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL): Predictive Prognostic Model for Survival. Blood, 2015, 126, 3722-3722.	0.6	0
298	Liposomal Vincristine (Marqibo) Combined with Hyper-Cmad As Frontline Therapy for Patients with Acute Lymphoblastic Leukemia: A Result of a Phase II Clinical Trial. Blood, 2015, 126, 3720-3720.	0.6	0
299	The Impact of 20q Deletion on Clinical Presentation, Treatment Response and Survival in Patients with Acute Myeloid Leukemia (AML): The University of Texas MD Anderson Cancer Center Experience. Blood, 2015, 126, 1369-1369.	0.6	0
300	Nilotinib or Dasatinib Front-Line Therapy in Patients (Pts) With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) With Pre-existing Liver and/or Renal dysfunction. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S138-S139.	0.2	0
301	A Single Case of Rosai-Dorfman Disease Marked by Pathologic Fractures, Kidney Failure, and Liver Cirrhosis Treated with Single-Agent Cladribine. Frontiers in Oncology, 2014, 4, 297.	1.3	10
302	Phase II Study of Combination of Hypercvad with Ponatinib in Front Line Therapy of Patients (pts) with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 2289-2289.	0.6	5
303	Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS). Blood, 2014, 124, 4640-4640.	0.6	2
304	Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study. Blood, 2014, 124, 4666-4666.	0.6	1
305	Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab As Frontline Therapy for Adults with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 5277-5277.	0.6	4
306	Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy. Blood, 2014, 124, 534-534.	0.6	1

#	ARTICLE	IF	CITATIONS
307	Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Salvage Therapy for Adult Patients with Refractory/Relapse (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 964-964.	0.6	2
308	Ten-year follow up of patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with 400 mg or 800 mg of imatinib daily.. Journal of Clinical Oncology, 2014, 32, 7024-7024.	0.8	2
309	A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis.. Journal of Clinical Oncology, 2014, 32, 7111-7111.	0.8	1
310	Outcome of Patients (pts) with Therapy-Related De Novo Acute Myeloid Leukemia (t-de novo AML): Single Institution Experience. Blood, 2014, 124, 2273-2273.	0.6	0
311	Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium. Blood, 2014, 124, 4641-4641.	0.6	0
312	Chronic Myeloid Leukemia in Chronic Phase: Survival in the Era of Tyrosine Kinase Inhibitors Is Similar to That of the General Population in All Age Groups. Blood, 2014, 124, 1801-1801.	0.6	1
313	Prognostic Factors for Outcome in Patients (pts) with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody. Blood, 2014, 124, 2288-2288.	0.6	0
314	Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Blood, 2014, 124, 4538-4538.	0.6	1
315	Long-Term Outcome of Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Single-Institution Experience. Blood, 2014, 124, 1924-1924.	0.6	0
316	Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA) Failure: Primary Resistance (PriRes) Vs. Secondary Resistance (SecRes). Blood, 2014, 124, 1922-1922.	0.6	0
317	Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy. International Journal of Hematology, 2013, 98, 702-707.	0.7	26
318	Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 1227-1232.	2.0	34
319	Clinical Safety and Efficacy Of Nilotinib Or Dasatinib In Patients (Pts) With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) With Pre-Existing Liver and/Or Renal Dysfunction. Blood, 2013, 122, 1500-1500.	0.6	0
320	Impact of t (11;14) on the outcome of autologous hematopoietic cell transplantation (Auto-HCT) in multiple myeloma.. Journal of Clinical Oncology, 2012, 30, 8040-8040.	0.8	0